课题基金 / 基金详情

Targeting peripheral CCR2 macrophages in traumatic brain injury

Targeting peripheral CCR2 macrophages in traumatic brain injury
靶向外伤性脑损伤中的外周 CCR2 巨噬细胞
批准号:
8834690
负责人:
Josh Morganti
金额:
$5.6万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-15 至 2016-09-14

项目摘要

项目成果

Josh Morganti的其他基金

相关文献

中文摘要
翻译
描述(申请人提供):在美国,每年至少有170万人遭受创伤性脑损伤(TBI);在美国33%的与伤害相关的死亡中,创伤性脑损伤是一个促成因素。据估计,有320万至530万人长期患有脑损伤的身体、认知和心理健康残疾,每年的直接和间接成本估计超过800亿美元。此外,海外部署归来的退伍军人的创伤性脑损伤病例迅速增加,加剧了这些调查结果。现在人们认识到,TBI是一个过程,而不是一个事件。有新的证据表明,这一过程可能会导致多种神经退行性疾病。在临床上,脑外伤是阿尔茨海默病和痴呆发生的最重要的环境危险因素之一。然而,这种联系的分子机制尚未确定。新的证据表明,神经炎症可能在脑外伤所致的神经病理中起关键作用,这是由于对主要未受影响的脑区,特别是海马体结构造成的非特异性继发性或‘旁观者’损伤。中枢神经系统炎症反应的主要效应细胞是作为中枢神经系统驻留组织巨噬细胞的小胶质细胞。最近在正电子发射断层扫描配基成像方面的研究表明,脑外伤的长期幸存者在最初的创伤后数年内持续激活这种先天反应。这一现象尤其令人困惑的是,无法可靠地区分驻留巨噬细胞(小胶质细胞)的影响和外周单核/巨噬细胞的损伤诱导的渗透,因为在激活时,每种细胞在功能和外观上都是无法区分的。因此,这些浸润性细胞在与脑外伤相关的神经病理中的作用尚不清楚。目的1:将确定外周来源的CCR2阳性巨噬细胞在脑外伤后的时间相关性蓄积。CX3CR1+/GFPCCR2+/RFP报告小鼠将使用受控皮质撞击方法诱导脑损伤,这种方法可以区分常驻和外周天然免疫细胞。我们将通过一个跨越损伤后急性期到慢性期的全面时间过程来检查外周巨噬细胞在脑中的积聚及其炎症情况。初步研究表明,该模型诱导了海马区依赖的认知功能障碍,CCR2细胞浸润显著增加,以及伴随而来的促炎介质的产生。这一目标的结果将检验创伤性脑损伤与周围巨噬细胞积聚的关系,以及它们随时间变化的炎症特征。目的2:将确定靶向CCR2的药理学效果,以减轻脑损伤诱导的促炎反应和最终的认知功能障碍。初步数据表明,使用一种新的I相拮抗剂靶向CCR2阳性巨噬细胞可显著减少损伤后外周巨噬细胞的聚集。此外,这种治疗模式显著减少了多种促炎/神经毒性反应的表达。由于AIM将确定AIM 2的治疗基础,我们将扩展治疗范式,以涵盖外周巨噬细胞浸润的高峰,以检查该治疗方法在改善创伤后慢性期脑损伤诱导的海马区依赖认知功能障碍方面的效果。
英文摘要
DESCRIPTION (provided by applicant): Each year in the United States, at least 1.7 million people suffer traumatic brain injury (TBI); it is a contributing factor in 33% of all injury-relate US deaths. An estimated 3.2 to 5.3 million people live with the long-term physical, cognitive, and psychological health disabilities of TBI, with annual direct and indirect costs estimated at over $80 billion. Moreover, these findings are compounded by the rapid increase in TBI cases from returning veterans of overseas deployments. It is now being recognized that TBI is a process, not an event. There is emerging evidence that this process can lead to multiple neurodegenerative disorders. Clinically, TBI is one of the most powerful environmental risk factors for the development of Alzheimer's disease and dementia. However, a molecular mechanism for this association has not been identified. Emerging evidence suggests that neuroinflammation may play a pivotal role in TBI-induced neuropathology as a result of non-specific secondary or 'bystander' injury to primarily unaffected brain regions, notably the hippocampal formation. The primary effectors of CNS neuroinflammatory response are the microglia, which act as the CNS' resident tissue macrophage. Recent work in positron emission tomography ligand imaging has shown that long-term survivors of TBI have persistent activation of this innate response for years following the initial trauma. Particularly confounding to this phenomenon is the inability to reliably distinguish resident macrophage (microglia) effects versus injury-induced infiltration of peripheral monocytes/macrophages, as upon activation, each is phenotypically indistinguishable in function and appearance. Therefore the role of these infiltrating cells in the neuropathology associated with TBI remains unclear. Aim 1: Will determine the time-related accumulation of peripherally derived CCR2 positive macrophages in the brain following TBI. Brain injury will be induced using the controlled cortical impact method on CX3CR1+/GFPCCR2+/RFP reporter mice, which allow the delineation of resident versus peripheral innate immune cells. We will examine peripheral macrophage accumulation and their inflammatory profile in the brain through a comprehensive time course spanning the acute through chronic phases following injury. Preliminary studies indicate that this model induces hippocampal-dependent cognitive dysfunction, a marked increase in CCR2 cell infiltration, as well as concomitant production of pro-inflammatory mediators. Results from this aim will examine the relationship between TBI and accumulation of peripheral macrophages and their inflammatory profile across time. Aim 2: Will determine the efficacy of targeting CCR2 pharmacologically to ameliorate TBI-induced pro- inflammatory response and ultimately cognitive dysfunction. Preliminary data suggest that targeting CCR2 positive macrophages using a novel phase-I antagonist significantly depletes peripheral macrophage accumulation following injury. Moreover, this treatment paradigm significantly decreased the expression of multiple pro-inflammatory/neurotoxic responses. As Aim will define the therapeutic basis for Aim 2, we will extend treatment paradigm to cover the peak of peripheral macrophage infiltration to examine the effects this treatment has on ameliorating TBI-induced hippocampal dependent cognitive dysfunction in the chronic phase following injury.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inflammatory contributions of astrocytic RelA in comorbid VCID/AD
  • 批准号:
    10401633
  • 项目类别:
  • 资助金额:
    $35.45万
  • 财政年份:
    2021
  • 负责人:
    Josh Morganti
  • 依托单位:
Contributions of astrocyte RelA signaling in aging-related neurodegenerative sequelae following TBI
  • 批准号:
    10536667
  • 项目类别:
  • 资助金额:
    $66.53万
  • 财政年份:
    2021
  • 负责人:
    Josh Morganti
  • 依托单位:
Inflammatory contributions of astrocytic RelA in comorbid VCID/AD
  • 批准号:
    10054775
  • 项目类别:
  • 资助金额:
    $200.65万
  • 财政年份:
    2020
  • 负责人:
    Josh Morganti
  • 依托单位:
Dystrophic functions of aged astrocytes following traumatic brain injury
  • 批准号:
    9789796
  • 项目类别:
  • 资助金额:
    $19.13万
  • 财政年份:
    2018
  • 负责人:
    Josh Morganti
  • 依托单位: